1 |
万谟彬,翁心华. 干扰素治疗慢性乙型肝炎专家建议(2010年更新)[J]. 中华传染病杂志,2010,28(4):193-200.
|
2 |
European association for the study of the liver. EASL clinical practice guidelines: Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242.
|
3 |
Lok AS, McMahan BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50:661-662.
|
4 |
Zhou B, Xiao L, Wang Z, et al. Geographical and ethnic distribution of the HBV C/D recombinant on the Qinghai-Tibet Plateau[J]. PLoS One,2011,6(4):5954-5963.
|
5 |
许正锯,潘兴南,魏开鹏, 等. HBV S基因变异与临床疾病的关系[J/CD]. 中华实验和临床感染病杂志:电子版,2013,7(2):70-74.
|
6 |
张振华,彭静,夏剑波, 等. 表面抗原和抗体双阳性慢性乙型肝炎病毒感染者病毒S基因的变异分析[J]. 中华肝脏病杂志,2009,17(4):266-270.
|
7 |
荆永正,杨建,张国英, 等. 烟台地区献血人群感染乙肝病毒血清学标志的表现模式[J]. 国际病毒学杂志,2011,18(5):150-153.
|
8 |
王社梁,董国君. 血清乙型肝炎表面抗原和表面抗体共阳性慢性HBV感染者病毒S基因变异分析[J]. 中华微生物学与免疫学杂志,2012,32(3):249-252.
|
9 |
Chen WL, Yang Z, Wei SJ, et al. Sequence analysis of hepatitis B virus S gene "a" determinant in patients with positive HBsAg and anti-HBs[J]. Chin J Clin Infect Dis,2009,2(6):23-25.
|
10 |
Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology,2008,47(2):428-434.
|
11 |
Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol,2007,5(12):1462-1468.
|
12 |
窦晓光,侯金林. 应答指导治疗策略在聚乙二醇干扰素治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎患者中的应用[J]. 中华传染病杂志,2013,31(10):623-625.
|
13 |
陆忠华,陈卫,王娟华, 等. 220例慢性乙型肝炎病毒携带者病理特点及5年随访[J]. 南京医科大学学报(自然科学版),2009,29(4):530-533.
|
14 |
倪俊明,孙梅,吴旭平. 国产荧光定量PCR与COBAS AmpliPrep/COBAS Taqman V 2.0检测HBV DNA结果比较[J]. 临床检验杂志,2014,32(5):398-399.
|
15 |
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57(1):167-185.
|